Literature DB >> 8611406

P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer.

A Costa1, R Silvestrini, C Mochen, C Lequaglie, P Boracchi, A Faranda, G Vessecchia, G Ravasi.   

Abstract

The identification of biomarkers to complement pathological stage for a more accurate prognosis and help clinicians decide on treatment is still an open problem for patients with lung cancer. Expression of P53 protein was detected by an immunohistochemical approach using the monoclonal antibody PAb1801 on paraffin-embedded sections of tumours obtained surgically from 102 stage II - IIIa patients with non-small-cell lung cancer (52 squamous cell carcinomas, 50 adenocarcinomas). [3H]Thymidine labelling index, an indicator of the S-phase cell fraction, was evaluated on histological sections of [3H]thymidine-labelled tumour samples. DNA ploidy was defined by flow cytometric analysis on frozen tumour tissue. The biomarkers, histology and pathological stage were analysed in relation to relapse-free survival in univariate and multivariate analyses. Stage and interaction between [3H]thymidine labelling index and histology provided significant prognostic information for the overall series. [3H]thymidine labelling index was an independent prognostic indicator of 3 year relapse-free survival in patients with adenocarcinoma. The results indicate the importance of cell proliferation to complement prognostic information provided by pathological stage in patients with stage II-IIIa adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611406      PMCID: PMC2074267          DOI: 10.1038/bjc.1996.163

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature.

Authors:  P Marino; S Pampallona; A Preatoni; A Cantoni; F Invernizzi
Journal:  Chest       Date:  1994-09       Impact factor: 9.410

2.  p53 in non-small-cell lung cancer.

Authors:  B Passlick; J R Izbicki; G Riethmüller; K Pantel
Journal:  J Natl Cancer Inst       Date:  1994-05-18       Impact factor: 13.506

3.  Clinical relevance of cell kinetics in breast cancer.

Authors:  D Amadori; A Volpi; A Callea; L Amaducci; S Morgagni; E Magni; O Nanni
Journal:  Ann N Y Acad Sci       Date:  1993-11-30       Impact factor: 5.691

4.  p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers.

Authors:  A Costa; R Marasca; B Valentinis; M Savarino; A Faranda; R Silvestrini; G Torelli
Journal:  J Pathol       Date:  1995-05       Impact factor: 7.996

5.  Randomised clinical trial of adjuvant chemotherapy in patients with node-negative, fast-proliferating breast cancer.

Authors:  A Paradiso; A Mangia; A Barletta; A M Catino; A Giannuzzi; F Schittulli; N Radogna; S Longo; D Palmieri; F Marzullo
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas.

Authors:  O Mørkve; O J Halvorsen; R Skjaerven; L Stangeland; A Gulsvik; O D Laerum
Journal:  Anticancer Res       Date:  1993 May-Jun       Impact factor: 2.480

7.  Prognostic significance of Ki67 labelling in resected non small cell lung cancer.

Authors:  G V Scagliotti; M Micela; L Gubetta; E Leonardo; S Cappia; P Borasio; E Pozzi
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

8.  Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer.

Authors:  A E Filderman; G A Silvestri; C Gatsonis; D J Luthringer; J Honig; S D Flynn
Journal:  Am Rev Respir Dis       Date:  1992-09

9.  Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.

Authors:  M Ebina; S M Steinberg; J L Mulshine; R I Linnoila
Journal:  Cancer Res       Date:  1994-05-01       Impact factor: 12.701

10.  The relationship of p53 immunostaining to survival in carcinoma of the lung.

Authors:  R McLaren; I Kuzu; M Dunnill; A Harris; D Lane; K C Gatter
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

View more
  8 in total

1.  Clinical importance of correlations between p53 immunoreactivity and clinicopathological parameters in lung carcinoma.

Authors:  B A Dursun; L Memiş; A Dursun; H Bayiz; M Ozkul
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

2.  Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.

Authors:  Reiko Kameyama; Yuka Yamamoto; Kunihiko Izuishi; Ryusuke Takebayashi; Masanobu Hagiike; Makiko Murota; Masato Kaji; Reiji Haba; Yoshihiro Nishiyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-05       Impact factor: 9.236

3.  [18F]FLT PET for diagnosis and staging of thoracic tumours.

Authors:  Helmut Dittmann; Bernhard Matthias Dohmen; Frank Paulsen; Kai Eichhorn; Susanne Martina Eschmann; Marius Horger; Manfred Wehrmann; Hans Juergen Machulla; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-26       Impact factor: 9.236

4.  Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.

Authors:  Yuka Yamamoto; Yoshihiro Nishiyama; Shinya Ishikawa; Jun Nakano; Sung Soo Chang; Shuji Bandoh; Nobuhiro Kanaji; Reiji Haba; Yoshio Kushida; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-26       Impact factor: 9.236

5.  Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer.

Authors:  Yuka Yamamoto; Yoshihiro Nishiyama; Naruhide Kimura; Shinya Ishikawa; Masaya Okuda; Shuji Bandoh; Nobuhiro Kanaji; Masato Asakura; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-02       Impact factor: 9.236

6.  Relationship between TA01 and TA02 polypeptides associated with lung adenocarcinoma and histocytological features.

Authors:  T Hirano; K Fujioka; B Franzèn; K Okuzawa; K Uryu; H Shibanuma; K Numata; C Konaka; Y Ebihara; M Takahashi; H Kato; G Auer
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data.

Authors:  D Choma; J P Daurès; X Quantin; J L Pujol
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

8.  A pilot study of 4'-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer.

Authors:  Ryogo Minamimoto; Jun Toyohara; Hideyuki Ito; Ayako Seike; Yoko Miyata; Miyako Morooka; Momoko Okasaki; Kazuhiko Nakajima; Kimiteru Ito; Kiichi Ishiwata; Kazuo Kubota
Journal:  EJNMMI Res       Date:  2014-03-05       Impact factor: 3.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.